Advertisement


Emily L. Podany, MD, on Metastatic Breast Cancer: Racial Differences in Genomic Profiles and Targeted Treatment Use

2024 ASCO Annual Meeting

Advertisement

Emily L. Podany, MD, of Washington University, St. Louis, discusses disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used (Abstract 1017). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The study that I'm presenting is a multicenter consortium study. It consists of 1,327 patients that we looked at both genomic data through the liquid biopsy Guardant360 and clinical data that we got manually from the electronic medical record system. We decided to use this large multi-consortium database to ask questions about targeted treatment use in Black versus White patients. So we found that Black and White patients had equal incidence of PIK3CA mutations. But despite this equal incidence, they had differences in targeted treatment use. Black patients ended up having significantly less targeted treatment use than White patients in this dataset. Specifically, this was for these PI3 kinase inhibitor use. When we looked at mTOR inhibitor use and CDK4/6 inhibitor use, which does not require a specific finding in ctDNA or liquid biopsy, we actually didn't find any differences. So the only targeted treatment use differences was when there was a specific targeted finding in the ctDNA profiling. The other thing we looked at after that was we looked at overall survival in this cohort. We'd previously reported overall survival in the overall 1,327 patients, and then we looked specifically at HR-positive HER2-negative metastatic breast cancer patients, and we looked at ER positive, PR negative HER2 negative, and ER positive, PR positive HER2 negative. The PR-negative patients did significantly worse in terms of overall survival and Black patients with ER positive, PR negative HER2 negative did significantly worse than White patients with the same profile. Finally, we looked at clinical trial enrollment, so we looked at whether the patients with this PIK3CA mutation with metastatic breast cancer were enrolled in clinical trials at the same rate between Black and White patients. So we found that Black patients were significantly less likely to be enrolled in a clinical trial than White patients.

Related Videos

Colorectal Cancer

Jeanne Tie, MD, MBChB, on Colon Cancer: New Data on ctDNA Guiding Adjuvant Therapy

Jeanne Tie, MD, MBChB, of Peter MacCallum Cancer Centre, discusses data on survival and updated 5-year results from the DYNAMIC trial, which supports a role for circulating tumor DNA (ctDNA) analysis, including serial sampling, in the management of patients with stage II colon cancer (Abstract 108).

Breast Cancer

Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection

Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre, discusses a circulating tumor DNA (ctDNA) analysis from a cohort of patients with early-stage breast cancer who were enrolled in the monarchE trial. This large cohort was studied to look at the usefulness of a personalized tumor-informed assay for ctDNA detection in early stage high-risk patients (LBA507).

Breast Cancer

Ana C. Garrido-Castro, MD, on Managing Metastatic Breast Cancer in 2024

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, discusses recent approvals of multiple novel therapies for metastatic breast cancer, weighing their potential benefits and risks, understanding the mechanisms that drive response and resistance, and exploring how to optimally sequence them to enhance survival and quality of life.

Gynecologic Cancers

Don S. Dizon, MD, on Ovarian and Other Extrarenal Clear Cell Carcinomas: Update on Nivolumab and Ipilimumab

Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).

Skin Cancer

Pauline Funchain, MD and Paolo A. Ascierto, MD, on Advanced Melanoma: Results From the RELATIVITY-048 Trial

Pauline Funchain, MD, of Stanford University and the Stanford Cancer Institute, and Paolo A. Ascierto, MD, of Italy’s Istituto Nazionale Tumori and IRCCS Fondazione G. Pascale, discuss efficacy and safety findings of the triplet therapy nivolumab, relatlimab-rmbw, and ipilimumab in patients with advanced melanoma (Abstract 9504).

 

Advertisement

Advertisement




Advertisement